# Hopstem Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hopstem-biotechnology

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.hopstem.com
- Total disclosed funding: $87M
- Latest round: Series C (Aug 10, 2026)
- Investors on record: 12

## About

Based in Zhejiang, China, and founded in 2017, Hopstem Biotechnology Co., Ltd., trading as Hopstem Biotechnology, operates as a nerve and stem cells developer that focuses on the diagnosis and research of nervous system disease. In August 2026, Hopstem Biotechnology raised nearly CNY 200 million in series C funding from Tasly Capital Holdings Limited, Haibang Venture, Jinkong Fund Management and Zhuhai Longmen Capital Management.

The company focuses on stem cell therapy for neurological diseases. At the same time, the company provides a variety of innovative scientific research products and services, including high-maturity human nerve cells and internationally leading brain organ products, as well as iPSC reprogramming, clinical-grade iPSC directed differentiation cell product joint development and authorization, and human in vitro disease models, drug screening, neurotoxicity testing, etc.

The company's revenue is generated by providing high-quality human neural cells, 3D brain organoids, supporting stem cell culture and neural differentiation and maturation reagents, and technical services including gene editing.

The company will use the latest funding to accelerate the clinical development and commercial production preparation of the company's products across multiple indications.

## Funding rounds

- Series C, Aug 10, 2026, $30M — Haibang Venture, Zhuhai Longmen Capital Management, Jinkong Fund Management, Tasly Capital Holdings Limited
- Series B, Nov 1, 2021, $40M — Lilly Asia Ventures, YuanBio Venture, GL Ventures
- Series A, May 28, 2021, $16M — YuanBio Venture, Zhuhai Longmen Capital Management, Huacheng Venture Capital
- Series A, Dec 9, 2020 — Zhuhai Longmen Capital Management, Huacheng Venture Capital
- Series A, Dec 25, 2018 — Delta Capital
- Angel, Jul 17, 2017, $1.8M — Cybernaut Investment Group, Empower Investment, HEO Ventures

## Investors

- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Angel
- Empower Investment (https://capitalatlas.ai/funds/empower-investment) — Angel
- HEO Ventures — Angel
- Delta Capital (https://capitalatlas.ai/funds/delta-capital) — Series A
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series A, Series C
- Huacheng Venture Capital (https://capitalatlas.ai/funds/huacheng-venture-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- Haibang Venture — Series C
- Jinkong Fund Management (https://capitalatlas.ai/funds/jinkong-fund-management) — Series C
- Tasly Capital Holdings Limited (https://capitalatlas.ai/funds/tasly-capital-holdings-limited) — Series C